biosimilars | pharmaphorum

Monday 6 April 2026

biosimilars

News

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.

News

NHS saving £300m with Humira biosimilar deal

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

mundipharma

Mundipharma's Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.

News

mundipharma

Mundipharma appoints former GSK exec as CFO

The Mundipharma network of independent pharma companies has appointed Arnaud Breabout as chief financial officer.

Partner Content

J+D, Pharma Forecasting Experts Partner with Epiphany, Oncology Data Experts

Partner Content

J+D, Pharma Forecasting Experts Partner with Epiphany, Oncol...

J+D have brought several innovations to market this year including Online Training, th

Oncology

approximate the DNA molecule on a blue background

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.